FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:630 February 26, 1998 Number 9

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by Alan J. Thompson, Chris Polman, and Reinhard Hohlfeld. 360 pp., illustrated. London, Martin Dunitz, 1997. (Distributed by Mosby, St. Louis.) $99.50. ISBN 1-85317-428-9.

The incidence of multiple sclerosis is about 5 to 6 per 100,000 population, and despite the benefit of national support groups, patients are often devastated when the diagnosis is made. Equally, physicians caring for them feel helpless in the face of an illness for which there is no known cure or cause. Only in the past few years have definitive suppressant agents become available, but even these reduce the incidence of clinical relapses in remitting and relapsing multiple sclerosis by only about 30 percent, and their effect can be proved only in large controlled series. These agents are not without . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.